Dissecting kinase signaling pathways

Drug Discovery Today

Volumn 12, Issue 17-18, 2007, Pages 717-724

  Boyle, Scott N ^a   Koleske, Anthony J ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; LAPATINIB; PHOSPHOPROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; TRASTUZUMAB;

CANCER; DIABETES MELLITUS; DNA LIBRARY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME SUBSTRATE; GENETIC PROCEDURES; LOW THROUGHPUT APPROACH; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TECHNIQUE; VALIDITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; PYRIMIDINES; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 34548462507     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.07.019     Document Type: Review

References (68)

1. Zimmermann J., et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. (Weinheim) 329 (1996) 371-376
2. Tuveson D.A., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20 (2001) 5054-5058
3. Buchdunger E., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
4. Advani A.S., and Pendergast A.M. Bcr-Abl variants: biological and clinical aspects. Leuk. Res. 26 (2002) 713-720
5. O'Dwyer M.E., et al. STI571 as a targeted therapy for CML. Cancer Invest. 21 (2003) 429-438
6. Demetri G.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
7. Slamon D.J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
8. Tsuda H., et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 49 (1989) 3104-3108
9. Lewis G.D., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37 (1993) 255-263
10. Sliwkowski M.X., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26 Suppl. 12 (1999) 60-70
11. Baselga J., et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58 (1998) 2825-2831
12. Nahta R., et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol. Cancer Ther. 6 (2007) 667-674
13. Xia W., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 (2002) 6255-6263
14. Moy B., and Goss P.E. Lapatinib: current status and future directions in breast cancer. Oncologist 11 (2006) 1047-1057
15. Manning G., et al. The Protein Kinase Complement of the Human Genome. Science 298 (2002) 1912-1934
16. Johnson S.A., and Hunter T. Kinomics: methods for deciphering the kinome. Nat. Meth. 2 (2005) 17
17. Ross A.H., et al. Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to a synthetic hapten. Nature 294 (1981) 654-656
18. Kanner S.B., et al. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3328-3332
19. Kanner S.B., et al. Novel tyrosine phosphorylations accompany the activation of pp60c-src during chemical carcinogenesis. Oncogene 4 (1989) 295-300
20. Kanner S.B., et al. Immunoaffinity purification of tyrosine-phosphorylated cellular proteins. J. Immunol. Methods 120 (1989) 115-124
21. Wu H., et al. Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol. Cell Biol. 11 (1991) 5113-5124
22. Boyle S.N., et al. A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave formation. Curr. Biol. 17 (2007) 445-451
23. Grant S.G., et al. Focal adhesion kinase in the brain: novel subcellular localization and specific regulation by Fyn tyrosine kinase in mutant mice. Genes Dev. 9 (1995) 1909-1921
24. Martin K., et al. Quantitative analysis of protein phosphorylation status and protein kinase activity on microarrays using a novel fluorescent phosphorylation sensor dye. Proteomics 3 (2003) 1244-1255
25. Hernandez S.E., et al. Adhesion-dependent regulation of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Curr. Biol. 14 (2004) 691-696
26. Shah K., et al. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3565-3570
27. Dephoure N., et al. Combining chemical genetics and proteomics to identify protein kinase substrates. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17940-17945
28. Allen J.J., et al. Bio-orthogonal affinity purification of direct kinase substrates. J. Am. Chem. Soc. 127 (2005) 5288-5289
29. Allen J.J., et al. A semisynthetic epitope for kinase substrates. Nat. Methods 4 (2007) 511-516
30. Liu Y., et al. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities. Biochemistry 39 (2000) 14400-14408
31. Habelhah H., et al. Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J. Biol. Chem. 276 (2001) 18090-18095
32. Shah K., and Shokat K.M. A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Chem. Biol. 9 (2002) 35-47
33. Bishop A.C., et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407 (2000) 395-401
34. Shah K., and Vincent F. Divergent roles of c-Src in controlling platelet-derived growth factor-dependent signaling in fibroblasts. Mol. Biol. Cell 16 (2005) 5418-5432
35. Manning B.D., and Cantley L.C. Hitting the target: Emerging technologies in the search for kinase substrates. Sci. STKE 2002 162 (2002) pe49
36. Songyang Z., et al. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4 (1994) 973-982
37. Kemp B.E., and Pearson R.B. Design and use of peptide substrates for protein kinases. Methods Enzymol. 200 (1991) 121-134
38. al-Obeidi F.A., et al. Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers 47 (1998) 197-223
39. Kang C.M., et al. The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes Dev. 19 (2005) 1692-1704
40. Rychlewski L., et al. Target specificity analysis of the Abl kinase using peptide microarray data. J. Molec. Biol. 336 (2004) 307
41. Yang X., et al. A protein kinase substrate identified by the two-hybrid system. Science 257 (1992) 680-682
42. Alexandropoulos K., et al. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3110-3114
43. Alexandropoulos K., and Baltimore D. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein. Sin. Genes Dev. 10 (1996) 1341-1355
44. Lustig K.D., et al. Small pool expression screening: identification of genes involved in cell cycle control, apoptosis, and early development. Methods Enzymol. 283 (1997) 83-99
45. Stukenberg P.T., et al. Systematic identification of mitotic phosphoproteins. Curr. Biol. 7 (1997) 338-348
46. Zhu H., et al. Global analysis of protein activities using proteome chips. Science 293 (2001) 2101-2105
47. Feilner T., et al. High throughput identification of potential Arabidopsis mitogen-activated protein kinases substrates. Mol. Cell Proteom. 4 (2005) 1558-1568
48. Ptacek J., et al. Global analysis of protein phosphorylation in yeast. Nature 438 (2005) 679-684
49. Chamnongpol S., and Li X. SH3 domain protein-binding arrays. Methods Mol. Biol. 264 (2004) 183-189
50. Jones R.B., et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439 (2006) 168-174
51. Fang Y., et al. Membrane protein microarrays. J. Am. Chem. Soc. 124 (2002) 2394-2395
52. Ramachandran N., et al. Self-assembling protein microarrays. Science 305 (2004) 86-90
53. Boutell J.M., et al. Functional protein microarrays for parallel characterisation of p53 mutants. Proteomics 4 (2004) 1950-1958
54. Hesselberth J.R., et al. Comparative analysis of Saccharomyces cerevisiae WW domains and their interacting proteins. Genome Biol. 7 (2006) R30
55. Hall D.A., et al. Regulation of gene expression by a metabolic enzyme. Science 306 (2004) 482-484
56. Jung G.Y., and Stephanopoulos G. A functional protein chip for pathway optimization and in vitro metabolic engineering. Science 304 (2004) 428-431
57. Michaud G.A., et al. Analyzing antibody specificity with whole proteome microarrays. Nat. Biotechnol. 21 (2003) 1509-1512
58. Mann M., et al. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol. 20 (2002) 261-268
59. Gillardon F., et al. Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor. Proteomics 5 (2005) 1299-1307
60. Gillardon F., et al. Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. J. Cell Biochem. 95 (2005) 817-826
61. Tanis K.Q., et al. Two distinct phosphorylation pathways have additive effects on abl family kinase activation. Mol. Cell Biol. 23 (2003) 3884-3896
62. House C., et al. The influence of basic residues on the substrate specificity of protein kinase C. J. Biol. Chem. 262 (1987) 772-777
63. Bylund D.B., and Krebs E.G. Effect of denaturation on the susceptibility of proteins to enzymic phosphorylation. J. Biol. Chem. 250 (1975) 6355-6361
64. Prowse C.N., et al. Catalytic reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry 39 (2000) 6258-6266
65. Hibi M., et al. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7 (1993) 2135-2148
66. Fletterick R.J., and Madsen N.B. The structures and related functions of phosphorylase a. Annu. Rev. Biochem. 49 (1980) 31-61
67. Lowenstein E.J., et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70 (1992) 431-442
68. DiDonato J., et al. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell Biol. 16 (1996) 1295-1304